MaaT Pharma informs on the completion of patient recruitment for the Phase 2a clinical trial sponsored by AP-HP2 and in collaboration with INRAE and Institut Gustave Roussy, evaluating MaaT013, the Company?s lead product candidate, in combination with immune checkpoint inhibitors (ICI), ipilimumab (Yervoy®) and nivolumab (Opdivo®). A total of 70 patients have been enrolled in 5 different centers in France in the randomized controlled Phase 2a PICASSO trial, which started in April 2022. The Company provided MaaT013 drug candidate and placebo and will contribute to the microbiome profiling of patients using its proprietary gutPrint® research engine.

The unblinding will be done at Week 27 (W27) to assess the primary endpoint which is safety. In parallel, the first efficacy data will be made available, assessed by the best overall response rate, rated by immunological Response Evaluation Criteria in Solid Tumors (iRECIST; 19). Having reached this key recruitment milestone, the first publication will be submitted at the end of 2024 or in the first quarter of 2025.

The PICASSO trial is funded by the Directorate of Health Care Supply and operated by the French National Cancer Institute as part of a call for projects.